Pfizer (PFE) News Today

Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of encouraging clinical progress, solid quarterly results, updated analyst targets and emerging headwinds from legislative and funding shifts.

• Positive Sentiment: Progress updates on key clinical trials across multiple myeloma, migraine, pediatric antibiotics, COVID-19/influenza, sickle cell disease and RSV demonstrate the depth of Pfizer’s R&D pipeline. Pfizer’s MAGNETISMM-6 Study: A New Horizon in Multiple Myeloma Treatment
• Positive Sentiment: Strong Q2 performance with earnings topping estimates and management raising its full-year profit outlook drove a positive market reaction. Stock Price Up 4% Following Better-Than-Expected Earnings
• Neutral Sentiment: Citi, Morgan Stanley and Bank of America each lifted price targets to $26, $33 and $28 while maintaining neutral/equal-weight ratings on PFE. Citigroup Forecasts Strong Price Appreciation & Morgan Stanley Price Target Raised to $33.00
• Neutral Sentiment: Analysts suggest focusing on dividends and buybacks amid EPS uncertainties following Pfizer’s Q2 update. Pfizer Q2: Dividends Speak Louder Than EPS
• Negative Sentiment: Leerink Partners cut its Q3 EPS forecast to $0.80 from $0.98, signaling growing earnings pressure. Leerink Partners Issues Negative Estimate
• Negative Sentiment: The proposed H.R.4668 would remove liability shields for vaccine makers, potentially exposing Pfizer to increased litigation risks. End the Vaccine Carveout Act (H.R.4668)
• Negative Sentiment: Jim Cramer warns that Pfizer’s shareholder base is “getting very restive,” underscoring growing investor unease. Jim Cramer Warning
• Negative Sentiment: The Department of HHS ending mRNA vaccine support shifts funding away from Pfizer’s joint projects. Pfizer Faces Funding Shift as HHS Ends mRNA Support
• Negative Sentiment: RFK Jr. halts $500 million in mRNA vaccine projects previously backed by Pfizer, potentially delaying pipeline initiatives. RFK Jr. Halts $500M mRNA Projects